SCYNEXIS soars on interim results of Phase 3 study of fungal treatment

SCYNEXIS Inc (NASDAQ:SCYX) rallied Thursday after announcing positive results from the first interim analysis of a Phase 3 open-label study.

The biotech said in a statement that its oral ibrexafungerp salvage treatment of hard-to-treat mucocutaneous and invasive fungal infections showed clinical benefits in 17 out of 20 patients.

The stock of the Jersey City, New Jersey company surged 69% to $1.22 in Thursday’s Nasdaq trading.

READ: Scynexis unveils favorable Phase 2b trials for yeast infection drug

“The positive results of this first interim analysis met all of our goals,” said Dr Marco Taglietti, CEO of SCYNEXIS.

Eleven patients achieving a complete or partial response and six patients a stable disease response, according to SCYNEXIS. Only two patients did not respond to ibrexafungerp treatment and the outcome for one patient was considered indeterminate.

Salvage therapy is applied after a patient fails to respond to standard therapy. In an open-label trial, both researchers and participants know what is being administered. Mucocutaneous junctions are found in areas such as the lips and nostrils. 

The 20 patients evaluated in the interim analysis suffered from a variety of severe conditions, including esophageal candidiasis, intra-abdominal abscesses and oropharyngeal candidiasis.

The most common fungal species were Candida glabrata and Candida krusei, two highly resistant organisms, according to the company. The ibrexafungerp treatment ranged from seven to 90 days, with a mean duration of 36.4 days.

Contact Dennis Fitzgerald at [email protected]

Story by ProactiveInvestors